These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28339500)

  • 41. HIV infection and zidovudine use in childbearing women.
    Sia J; Paul S; Martin RM; Cross H
    Pediatrics; 2004 Dec; 114(6):e707-12. PubMed ID: 15545619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Placental Mitochondrial Toxicity, Oxidative Stress, Apoptosis, and Adverse Perinatal Outcomes in HIV Pregnancies Under Antiretroviral Treatment Containing Zidovudine.
    Hernández S; Catalán-García M; Morén C; García-Otero L; López M; Guitart-Mampel M; Milisenda J; Coll O; Cardellach F; Gratacós E; Miró Ò; Garrabou G
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):e113-e119. PubMed ID: 28234688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities?
    Jungmann EM; Mercey D; DeRuiter A; Edwards S; Donoghue S; Booth T; Mohan D; Lyall H; Taylor GP
    Sex Transm Infect; 2001 Dec; 77(6):441-3. PubMed ID: 11714944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.
    Mandelbrot L; Landreau-Mascaro A; Rekacewicz C; Berrebi A; Bénifla JL; Burgard M; Lachassine E; Barret B; Chaix ML; Bongain A; Ciraru-Vigneron N; Crenn-Hébert C; Delfraissy JF; Rouzioux C; Mayaux MJ; Blanche S;
    JAMA; 2001 Apr; 285(16):2083-93. PubMed ID: 11311097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse fetal and infant outcomes among HIV-infected women who received either nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based antiretroviral therapy for prevention of mother-to-child transmission.
    Masaba R; Borkowf CB; Girde S; Zeh C; Ndivo R; Nyang'au I; Achola K; Thomas TK; Lecher SL
    AIDS; 2018 Jul; 32(12):1625-1632. PubMed ID: 30001243
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana.
    Dryden-Peterson S; Jayeoba O; Hughes MD; Jibril H; Keapoletswe K; Tlale J; Modise TA; Asmelash A; Moyo S; van Widenfelt E; Makhema J; Essex M; Shapiro RL; Lockman S
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):353-7. PubMed ID: 21792062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-utero exposure to antiretrovirals and neurodevelopment among HIV-exposed-uninfected children in Botswana.
    Chaudhury S; Mayondi GK; Williams PL; Leidner J; Shapiro R; Diseko M; Ajibola G; Holding P; Tepper V; Makhema J; Petlo C; Seage GR; Lockman S; Kammerer B
    AIDS; 2018 Jun; 32(9):1173-1183. PubMed ID: 29547434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
    Fowler MG; Qin M; Fiscus SA; Currier JS; Flynn PM; Chipato T; McIntyre J; Gnanashanmugam D; Siberry GK; Coletti AS; Taha TE; Klingman KL; Martinson FE; Owor M; Violari A; Moodley D; Theron GB; Bhosale R; Bobat R; Chi BH; Strehlau R; Mlay P; Loftis AJ; Browning R; Fenton T; Purdue L; Basar M; Shapiro DE; Mofenson LM;
    N Engl J Med; 2016 Nov; 375(18):1726-1737. PubMed ID: 27806243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.
    Williams PL; Hazra R; Van Dyke RB; Yildirim C; Crain MJ; Seage GR; Civitello L; Ellis A; Butler L; Rich K;
    AIDS; 2016 Jan; 30(1):133-44. PubMed ID: 26731758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection.
    Sperling RS; Stratton P; O'Sullivan MJ; Boyer P; Watts DH; Lambert JS; Hammill H; Livingston EG; Gloeb DJ; Minkoff H
    N Engl J Med; 1992 Mar; 326(13):857-61. PubMed ID: 1542322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiretroviral interventions for preventing breast milk transmission of HIV.
    White AB; Mirjahangir JF; Horvath H; Anglemyer A; Read JS
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD011323. PubMed ID: 25280769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
    Money D; Lee T; O'Brien C; Brophy J; Bitnun A; Kakkar F; Boucoiran I; Alimenti A; Vaudry W; Singer J; Sauve LJ;
    BJOG; 2019 Oct; 126(11):1338-1345. PubMed ID: 31188522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of community-based support for pregnant women living with HIV: a cohort study in South Africa.
    Fatti G; Shaikh N; Eley B; Grimwood A
    AIDS Care; 2016; 28 Suppl 1(sup1):114-8. PubMed ID: 26922939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries.
    Sartorius BK; Chersich MF; Mwaura M; Meda N; Temmerman M; Newell ML; Farley TM; Luchters S;
    BMC Infect Dis; 2013 Nov; 13():522. PubMed ID: 24192332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study.
    Sperling RS; Shapiro DE; McSherry GD; Britto P; Cunningham BE; Culnane M; Coombs RW; Scott G; Van Dyke RB; Shearer WT; Jimenez E; Diaz C; Harrison DD; Delfraissy JF
    AIDS; 1998 Oct; 12(14):1805-13. PubMed ID: 9792381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral treatment initiation among HIV-infected pregnant women with low CD4(+) cell counts in Gaborone, Botswana.
    Chen JY; Ogwu AC; Svab P; Lockman S; Moffat HJ; Gaolathe T; Moilwa S; Størdal K; Dryden-Peterson S; Moffat C; Makhema J; Essex M; Shapiro RL
    J Acquir Immune Defic Syndr; 2010 May; 54(1):102-6. PubMed ID: 19864957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial.
    Drake AL; Roxby AC; Kiarie J; Richardson BA; Wald A; John-Stewart G; Farquhar C
    PLoS One; 2012; 7(4):e34635. PubMed ID: 22509337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study.
    Lorenzi P; Spicher VM; Laubereau B; Hirschel B; Kind C; Rudin C; Irion O; Kaiser L
    AIDS; 1998 Dec; 12(18):F241-7. PubMed ID: 9875571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
    Lallemant M; Amzal B; Sripan P; Urien S; Cressey TR; Ngo-Giang-Huong N; Klinbuayaem V; Rawangban B; Sabsanong P; Siriwachirachai T; Jarupanich T; Kanjanavikai P; Wanasiri P; Koetsawang S; Jourdain G; Le Coeur S;
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):313-322. PubMed ID: 32205720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.